A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 16, 2012

Integrase Inhibitor Dolutegravir Shows Promise in Drug-Resistant HIV

Phase III data show that the experimental integrase inhibitor dolutegravir, a combined effort from GlaxoSmithKline, Pfizer and Shionogi, fully suppressed viral loads among 63 percent of people with multi drug-resistant HIV, Bloomberg reports. Announcing the results of their joint VIKING-3 study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow, ViiV Healthcare said this third of four late-stage trials of dolutegravir sets the stage for regulatory filing by the end of the year.

ViiV tested the dolutegravir in 183 people with multiple antiretroviral (ARV) class resistance, including resistance to other integrase inhibitors—raltegravir and/or elvitegravir. After 24 weeks, 63 percent achieved an undetectable viral load, with only 3 percent discontinuing because of side effects. The most common side effects, each occurring in 5 percent of patients, included diarrhea, nausea and headache.

To read the Bloomberg article, click here.

To read the ViiV press release, click here.

Search: HIV, antiretroviral, dolutegravir, integrase, GlaxoSmith Kline, multi drug-resistant, VIKING-3, Glasgow, ViiV Healthcare, integrase inhibitor, reltegravir, elvitegravir, side effects.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine

    Palm Springs


    San Antonio

This could be you!
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.